个人简介

浙江大学求是特聘科研岗，教授，博士生导师，浙江省“万人计划”科技创新领军人才，浙江省高校高水平创新“肝病精准诊治”团队带头人，省151 人才。长期致力于慢乙肝重症化发病机制与精准诊治研究。主持“十三五”科技部重大专项1项，“十二五”科技部重大专项子任务1项，国自然联合基金重点支持项目1项，国家自然基金面上项目 4 项，浙江省重点研发计划2项。在高水平专业学术期刊上发表论文 80 余篇，近五年以通讯作者（含共同通讯）在《BMJ》、《Adv Sci》、《Genome Biol》、《Biotechnol Adve》和《J Hematol Oncol》等期刊发表论文30余篇。授权发明专利 10 余项，参编著作2部，多次获得教育部及浙江省科技进步奖。

专业擅长

主要从事传染病学的教学与科研工作。擅长重症肝病精准诊治和重大传染性疾病防治的基础与临床研究。

研究方向

 致力于从多角度解析乙肝重症化转归的机制，探索创建重症肝病精准诊疗的新技术。研究方向为HBV感染、慢乙肝转归、肝脏炎癌转化过程中的分子和免疫机制，肝病精准诊断和药物靶点及靶向治疗药物的研发工作。

成果奖项：（近五年主要成果及奖励情况）

近5年以通讯或共同通讯发表SCI论文31篇：

Shi D, Weng T, Wu J, Dai C, Luo R, Chen K, Zhu M, Lu X, Cheng L, Chen Q, Liu F, Wu Z, Wu H, Jin C, Guo M, Chen Z, Wu N, Yao H*, Zheng M*. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study. Front Immunol. 2021 Jul 20;12:708184.

Chen B, Wang W, Xu W, Ying L, Zhou C*, Zheng M*. Serum free light chain is associated with histological activity and cirrhosis in patients with chronic hepatitis B. Int Immunopharmacol. 2021 Jul 7;99:107881.

Ruan D, Shi Y, Wen J, Zheng N*, Zheng M*. Spatially-Aware Context Neural Networks. IEEE Trans Image Process. 2021 Jul 26;PP.

Ruan D, Shi Y, Jin L, Yang Q, Yu W, Ren H, Zheng W, Chen Y, Zheng N*, Zheng M*. An Ultrasound Image-Based Deep Multi-Scale Texture Network for Liver Fibrosis Grading in Patients with Chronic HBV Infection. Liver Int. 2021 Jul 5.

Chen Y, Yao H, Zhang N, Wu J, Gao S, Guo J, Lu X, Cheng L, Luo R, Liang X, Wong CCL*, Zheng M*. Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage. J Proteome Res. 2021 Jun 3.

Guo H, Chen S, Xie M, Zhou C*, Zheng M*. The complex roles of neutrophils in APAP-induced liver injury. Cell Prolif. 2021 Jun;54(6):e13040.

Chen S, Guo H, Xie M, Zhou C*, Zheng M*. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol. 2021 Apr 19;97:107609.

Li S, Shao J, Lou G, Wu C, Liu Y*, Zheng M*. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway. J Exp Clin Cancer Res. 2021 Feb 1;40(1):53.

Wang W, Shui L, Liu Y*, Zheng M*. C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases. Front Genet. 2021 Feb 2;12:598855.

 Xie M, Guo H, Lou G, Yao J, Liu Y, Sun Y*, Yang Z*, Zheng M*. Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis. J Cell Mol Med. 2021 Jan;25(2):840-854.

Yetian Dong, Tong Dai, Yujun Wei, Long Zhang, Min Zheng*, Fangfang Zhou*. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020 Oct 13;5(1):237. 

Xia C, Zhu W, Huang C, Lou G, Ye B, Chen F, Chen Z, Liu Y, Zheng M. Genetic polymorphisms of interleukin-6 influence the development of hepatitis B virus-related liver cirrhosis in the Han Chinese population. Infect Genet Evol. 2020 Apr 27;84:104331.

Shi Y, Zheng M*. Hepatitis B virus persistence and reactivation. BMJ. 2020 Sep 1;370:m2200.

Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, Yang B, Chen Z. An Overview of COVID-19. J Zhejiang Univ Sci B. 2020 May;21(5):343-360.

Zhang X, Peng Z, Li C, Wang Z, Wang C, Deng Z, Wu B, Cui Y, Wang Z, Cui CP*, Zheng M*, Zhang L*.Deubiquitylase OTUD6B Governs pVHL Stability in an Enzyme-Independent Manner and Suppresses Hepatocellular Carcinoma Metastasis. Adv Sci (Weinh). 2020 Jan.

Shao J, Li S, Liu Y*, Zheng M*.Extracellular vesicles participate in macrophage-involved immune responses under liver diseases. Life Sci. 2020 Jan.

Lou G, Chen L, Xia C, Wang W, Qi J, Li A, Zhao L, Chen Z, Zheng M*, Liu Y*.MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J ExpClin Cancer Res. 2020 Jan. 

Zhou X, Liu Z, Wang H, Liu X, Zhou Z, Tang J, Liu X*, Zheng M*, Shen Y. SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy. JOURNAL OF DRUG TARGETING. 2019 Jan.

Guo H, Xie M, Zhou C*, Zheng M*.The relevance of pyroptosis in the pathogenesis of liver diseases. Life Sci. 2019,223:69-73.

Ye B, Zhou C, Guo H, Zheng M*.Effects of BTK signalling in pathogenic microorganism infections. J Cell Mol Med. 2019 Jun.

Li Z, Leustean L, Inci F, Zheng M*, Demirci U*, Wang S*. Plasmonic-based platforms for diagnosis of infectious diseases at the point-of-care. Biotechnology Advances. 2019 Jul.

Xiao Z, Cheng G, Jiao Y, Pan C, Li R, Jia D, Zhu J, Wu C*, Zheng M*, Jia J*. Holo-Seq: single-cell sequencing of holo-transcriptome. Genome Biol. 2018 Feb.

Li S, Yao J, Xie M, Liu Y, Zheng M*. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J HematolOncol. 2018 Mar.

Liu Y*, Lou G, Li A, Zhang T, Qi J, Ye D, Zheng M*, Chen Z. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. EBioMedicine. 2018 Aug.

Jiao Y, Li R, Wu C, Ding Y, Liu Y, Jia D, Wang L, Xu X, Zhu J, Zheng M*, Jia J*.High-sensitivity HLA typing by Saturated Tiling Capture Sequencing (STC-Seq). BMC Genomics. 2018 Sep. 

Zheng W, Ye B, Liang X, Shui L, Lou G, Liu Y, Zheng M*. Hepatic macrophages are the cell source of hepatic procalcitonin in acute liver failure. Cell PhysiolBiochem. 2018 Sep. 

 Xie M, Yang Z, Liu Y, Zheng M*.The role of HBV-induced autophagy in HBV replication and HBV related-HCC. Life Sci. 2018 Apr.

Wu C, Jiao Y, Shen M, Pan C, Cheng G, Jia D, Zhu J, Zhang L, Zheng M*, Jia J*.Clustering-local-unique-enriched-signals (CLUES) promotes identification of novel regulators of ES cell self-renewal and pluripotency. PLoS One. 2018 Oct. 

Zheng W, Liang X, Shui L, Ye B, Lou G, Liu Y, Zheng M*.Serum Procalcitonin Correlates with Renal Function in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Cell PhysiolBiochem. 2018 Oct.

Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M*, Liu Y*.MiR-122 Modification Enhances the Therapeutic Efficacy of Adipose Tissue-derived MSCs against Liver Fibrosis. J Cell Mol Med. 2017 Jan.

 Xia C, Shui L, Lou G, Ye B, Zhu W, Wang J, Wu S, Xu X, Mao L, Xu W, Chen Z, Liu Y, Zheng M*. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. Sci Rep. 2017 Apr.

近5年作为第一发明人授权专利5项：

1) 与乙型肝炎肝硬化相关的IL-6基因rs2069837位点标志物及其应用, ZL201610115774.8, 授权公告日2020年7月21日。

2) 与乙型肝炎肝硬化相关的IL-6基因rs10499563位点标志物及其应用, ZL201610116342.9, 授权公告日2020年8月7日。

3) 与慢性乙型肝炎病毒感染相关的IL-6基因SNP标志物及其应用,ZL201610115674.5, 授权公告日2020年8月7日。

4) 与慢性乙型肝炎病毒感染相关的IL-6基因SNP标志物及其应用, ZL201610116319X, 授权公告日2020年5月5日。

5) 与慢性乙型肝炎病毒感染相关的IL-6基因rs2069852位点标志物及其应用。中国(ZL201610116382.3)。授权公告日2019年2月26日。

获奖情况：

1. 2019年，长三角生物工程优秀青年学者奖                                       

2. 2018年，浙江省高校高水平创新团队，团队带头人                                          

3. 2018年，病毒性肝炎发病机制及转归预警预测的基础研究，浙江省自然科学奖二等奖，排名2/5

4. 2018年，整合医学背景下的研究生“会聚式”协同培养模式的探索与实践，浙江省研究生教育学会教育成果奖特等奖，排名5/12  

社会任职

中华预防医学会微生态学分会第五届委员会  委员

中华医学会肝病学分会第七届委员会青年委员会  委员

中华医学会医学科学研究管理学分会青年委员会  委员

浙江省医学会肝病学分会第四届委员会 副主任委员

浙江省医学会科学研究管理分会委员会 副主任委员